Cart
sales@molnova.com
(Rac)-BRD0705
CAS No. 1597440-03-3
(Rac)-BRD0705( —— )
Catalog No. M26410 CAS No. 1597440-03-3
(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is an effective and selective inhibitor of GSK3α.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 335 | Get Quote |
|
| 10MG | 500 | Get Quote |
|
| 25MG | 806 | Get Quote |
|
| 50MG | 1098 | Get Quote |
|
| 100MG | 1485 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name(Rac)-BRD0705
-
NoteResearch use only, not for human use.
-
Brief Description(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is an effective and selective inhibitor of GSK3α.
-
Description(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is an effective and selective inhibitor of GSK3α.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorSGLT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1597440-03-3
-
Formula Weight321.424
-
Molecular FormulaC20H23N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (777.80 mM)
-
SMILESCCC1(C2=CNNC2=NC2=C1C(=O)CC(C)(C)C2)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Cheung CS, et al. Leachianone A as a potential anti-cancer drug by induction of apoptosis in human hepatoma HepG2 cells. Cancer Lett. 2007 Aug 18;253(2):224-35. Epub 2007 Mar 26.
molnova catalog
related products
-
(E)-3-(3,4-dichlorop...
(E)-3-(3,4-dichlorophenyl)-N-(2-(4-(methylsulfonyl)piperazin-1-yl)-2-oxoethyl)acrylamide is a chemical compound.
-
AMDE-1
AMDE-1 is a modulator of autophagy activity that acts by triggering autophagy in an Atg5-dependent manner, recruiting Atg16 to the pre-autophagosomal site and causing LC3 lipidation.
-
3-Hydroxy-2-methylpy...
3-Hydroxy-2-methylpyridine could as a promising molecular scaffold for the future development of novel fibrillization inhibitors.
